Sign In
Buy ZNTL
$4.74
-0.180 (-3.66%)
At Close: Jul 31, 2026
Zentalis Pharmaceuticals Announces Key Management Appointments
07:00am, Thursday, 12'th Dec 2024
Wendy Chang appointed Chief People Officer; Haibo Wang appointed Chief Business Officer Wendy Chang appointed Chief People Officer; Haibo Wang appointed Chief Business Officer
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:35pm, Monday, 02'nd Dec 2024
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small mole
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
01:14pm, Thursday, 21'st Nov 2024
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:04pm, Friday, 01'st Nov 2024
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small mole
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
02:03pm, Monday, 07'th Oct 2024
FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30,
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
10:25am, Tuesday, 17'th Sep 2024
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm
09:38pm, Monday, 16'th Sep 2024
NEW YORK , Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) b
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
09:00am, Monday, 16'th Sep 2024
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1.
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
07:00am, Monday, 16'th Sep 2024
Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 Company on track to present data from key clinical studies of azenosertib in the fourth quarter
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
07:00am, Monday, 09'th Sep 2024
Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates Azenosertib shows synergistic anti-tumor effects in combination wit
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:40pm, Tuesday, 03'rd Sep 2024
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small mol
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
01:01pm, Monday, 26'th Aug 2024
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
04:55pm, Monday, 19'th Aug 2024
NEW YORK--(BUSINESS WIRE)---- $ZNTL #NYTop100--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis�
Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm
11:00am, Monday, 19'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharma
Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm
11:00am, Sunday, 18'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharma
